TY - JOUR
T1 - Exploring Interplay of Polyunsaturated Fatty Acids
T2 - A Promising Approach for Treatment of Breast Cancer
AU - Alnbaheen, May Salem
AU - Ikbal, Abu Md Ashif
AU - Salem Bekhit, Mounir M.
AU - Bhattacharjee, Bedanta
AU - Dey, Nikita
AU - Sahu, Ram Kumar
AU - Khan, Jiyauddin
AU - Widyowati, Retno
AU - Miatmoko, Andang
N1 - Publisher Copyright:
© 2024 The Author(s).
PY - 2024/8/30
Y1 - 2024/8/30
N2 - Cancer, characterized by uncontrolled cell division and potential tissue spread, remains a significant health problem, with breast cancer being the most common in women, accounting for 25% of all cancer cases. Natural compounds have recently gained attention as they can improve the efficacy of cancer treatment. The aim of this study is to shed light on the potential benefits of polyunsaturated fatty acids in the treatment of breast cancer. Overexpression of tyrosine kinase receptors and mutations in the breast cancer gene-1 (BRCA1) and BRCA2 genes lead to breast cancer in women. Based on the findings of papers published in various scientific search engines, n-3 polyunsaturated fatty acid (PUFA) may reduce the likelihood of developing breast cancer due to their anti-inflammatory properties. According to several studies, women who consume more n-3 polyunsaturated fatty acids have a lower risk of breast cancer. n-3 polyunsaturated fatty acids regulate breast cancer by controlling the inflammatory mediators, gene expression transcription factor and signal transducer, peroxisome proliferator-activated receptor-gamma, B-cell lymphoma-2 (Bcl-2) associated X protein or B-cell lymphoma-2, Phosphatidylinositol 3-kinase or Protein kinase B, Nuclear factor-κB, and toll-like receptor-4. Polyunsaturated fatty acids are considered a successful treatment for breast cancer patients when combined with chemotherapy drugs. Doxorubicin is a first-line drug for the treatment of triple-negative breast cancer. Giving doxorubicin and polyunsaturated fatty acids together makes chemotherapy treatments for triple-negative breast cancer work better in the MDA-MB-468 and MDA-MB-231 cell lines. This review highlights the role of PUFAs in modulating cancer-related pathways, offering valuable insights for researchers, clinicians and the pharmaceutical industry in the fight against breast cancer.
AB - Cancer, characterized by uncontrolled cell division and potential tissue spread, remains a significant health problem, with breast cancer being the most common in women, accounting for 25% of all cancer cases. Natural compounds have recently gained attention as they can improve the efficacy of cancer treatment. The aim of this study is to shed light on the potential benefits of polyunsaturated fatty acids in the treatment of breast cancer. Overexpression of tyrosine kinase receptors and mutations in the breast cancer gene-1 (BRCA1) and BRCA2 genes lead to breast cancer in women. Based on the findings of papers published in various scientific search engines, n-3 polyunsaturated fatty acid (PUFA) may reduce the likelihood of developing breast cancer due to their anti-inflammatory properties. According to several studies, women who consume more n-3 polyunsaturated fatty acids have a lower risk of breast cancer. n-3 polyunsaturated fatty acids regulate breast cancer by controlling the inflammatory mediators, gene expression transcription factor and signal transducer, peroxisome proliferator-activated receptor-gamma, B-cell lymphoma-2 (Bcl-2) associated X protein or B-cell lymphoma-2, Phosphatidylinositol 3-kinase or Protein kinase B, Nuclear factor-κB, and toll-like receptor-4. Polyunsaturated fatty acids are considered a successful treatment for breast cancer patients when combined with chemotherapy drugs. Doxorubicin is a first-line drug for the treatment of triple-negative breast cancer. Giving doxorubicin and polyunsaturated fatty acids together makes chemotherapy treatments for triple-negative breast cancer work better in the MDA-MB-468 and MDA-MB-231 cell lines. This review highlights the role of PUFAs in modulating cancer-related pathways, offering valuable insights for researchers, clinicians and the pharmaceutical industry in the fight against breast cancer.
KW - anti-inflammatory
KW - breast cancer
KW - doxorubicin
KW - polyunsaturated fatty acids
KW - triple-negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=85205421057&partnerID=8YFLogxK
U2 - 10.23812/j.biol.regul.homeost.agents.20243809.463
DO - 10.23812/j.biol.regul.homeost.agents.20243809.463
M3 - Review article
AN - SCOPUS:85205421057
SN - 0393-974X
VL - 38
SP - 5769
EP - 5792
JO - Journal of Biological Regulators and Homeostatic Agents
JF - Journal of Biological Regulators and Homeostatic Agents
IS - 9
ER -